ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ZYME vs SLS // ALTMAN Z-SCORE & DEBT/EQUITY

Zymeworks Inc. (NASDAQ) VS. SELLAS Life Sciences Group Inc. (NASDAQ) • 15-METRIC TALLY: ZYME 2 — SLS 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZYME VS. SLS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ZYME SLS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.20% -21.80% -10.40 SLS /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -1.71% -1.38% -0.33 SLS /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 38.90% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 11.85 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 ZYME /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 60.4 38.7 +21.69 ZYME /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.02B $2.05B -$27.4M SLS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ZYME REV SLS REV ZYME GROSS % SLS GROSS % ZYME FCF SLS FCF
FY 2025 $106.0M $0 — — -$34.5M -$28.4M
FY 2024 $76.3M $0 — — -$112.0M -$35.4M
FY 2023 $76.0M $0 — — -$118.3M -$31.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZYME // BETA —
SLS // BETA —